120 related articles for article (PubMed ID: 9105258)
1. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays.
Bon GG; von Mensdorff-Pouilly S; Kenemans P; van Kamp GJ; Verstraeten RA; Hilgers J; Meijer S; Vermorken JB
Clin Chem; 1997 Apr; 43(4):585-93. PubMed ID: 9105258
[TBL] [Abstract][Full Text] [Related]
2. Quantification of MUC1 in breast cancer patients. A method comparison study.
Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
[TBL] [Abstract][Full Text] [Related]
3. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA.
Lynch DM; Rogers PE; Love JC; Salkas MJ; Skarphol KA; Gross ME; Lu MG; Petrides VH; Bruzek DJ; Cox JL; Jones KA; Kelley CA; Chan DW
Tumour Biol; 1998; 19(6):421-38. PubMed ID: 9817970
[TBL] [Abstract][Full Text] [Related]
5. Multicenter evaluation of the Bayer Immuno I CA 15-3 assay.
Cheli CD; Morris DL; Kish L; Goldblatt J; Neaman I; Allard WJ; Yeung KK; Wu AH; Moore R; Chan DW; Fritsche HA; Schwartz MK; Very DL
Clin Chem; 1998 Apr; 44(4):765-72. PubMed ID: 9554487
[TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical evaluation of a procedure for measuring CA 15-3 in the IMx analyser.
Ortega MD; Maestro ML; Encabo G; Varón C; Allende MT; Martinez I; Palacios G
Tumour Biol; 1996; 17(2):110-6. PubMed ID: 8658013
[TBL] [Abstract][Full Text] [Related]
7. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125.
Kenemans P; Bon GG; Kessler AC; Verstraeten AA; van Kamp GJ
Clin Chem; 1992 Aug; 38(8 Pt 1):1466-71. PubMed ID: 1643716
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
[TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of the Abbott IMx CA 15-3 assay.
van Kamp GJ; Bon GG; Verstraeten RA; Lynch D; Krikau M; Flückiger J; Ruibal A; Kenemans P
Clin Chem; 1996 Jan; 42(1):28-33. PubMed ID: 8565228
[TBL] [Abstract][Full Text] [Related]
10. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
van Dalen A
Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
[TBL] [Abstract][Full Text] [Related]
11. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
Molina R; Gion M; Gressner A; Troalen F; Auge JM; Holdenrieder S; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):612-22. PubMed ID: 18598203
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Gion M; Mione R; Leon AE; Dittadi R
Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.
Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352
[TBL] [Abstract][Full Text] [Related]
14. Automated immunofluorometric assay for MUC1.
Norum LF; Nilsson O; Nustad K
Tumour Biol; 2001; 22(3):169-75. PubMed ID: 11275795
[TBL] [Abstract][Full Text] [Related]
15. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1).
von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; van Kamp GJ; Kok A; van Uffelen K; Snijdewint FG; Paul MA; Meijer S; Hilgers J
Tumour Biol; 1998; 19(3):186-95. PubMed ID: 9591045
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.
von Mensdorff-Pouilly S; Gourevitch MM; Kenemans P; Verstraeten AA; Litvinov SV; van Kamp GJ; Meijer S; Vermorken J; Hilgers J
Eur J Cancer; 1996 Jul; 32A(8):1325-31. PubMed ID: 8869094
[TBL] [Abstract][Full Text] [Related]
17. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?
Klee GG; Schreiber WE
Arch Pathol Lab Med; 2004 Oct; 128(10):1131-5. PubMed ID: 15387710
[TBL] [Abstract][Full Text] [Related]
18. CA 15-3: a multicentre evaluation of automated and manual tests.
Huber PR; Bischof P; Kretschmer R; Truschnig M; Halwachs G; Schmidt M
Eur J Clin Chem Clin Biochem; 1996 Jan; 34(1):77-84. PubMed ID: 8704042
[TBL] [Abstract][Full Text] [Related]
19. New immunoassays for MUC1 in breast cancer.
Norum LF; Sauren AM; Rye PD; Nustad K
Tumour Biol; 2001; 22(4):216-22. PubMed ID: 11399946
[TBL] [Abstract][Full Text] [Related]
20. MUC1 serum assays in breast cancer: tumor specificities and reference levels.
Bjerner J; Norum LF; Nilsson O; Nustad K
Tumour Biol; 2002; 23(6):315-23. PubMed ID: 12677089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
